Rosiglitazone

Breastfeeding
  • TRADE NAMES: Avandamet (GSK); Avandaryl (GSK); Avandia (GSK)
  • INDICATIONS: Type II diabetes
  • CLASS: Antidiabetic, Thiazolidinedione
  • HALF-LIFE: 3–4 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

CYP2C8 inhibitors and inducers, Gemfibrozil, Grapefruit Juice, Letermovir, Paclitaxel, Rifampin, Teriflunomide

PREGNANCY CATEGORY: C

Thiazolidinediones, including rosiglitazone, cause or exacerbate congestive heart failure in some patients.

Contra-indicated in patients with established NYHA Class III or IV heart failure.

Avandaryl is rosiglitazone and glimepiride; Avandamet is rosiglitazone and metformin.

CONGESTIVE HEART FAILURE

See full prescribing information for complete boxed warning.

Our database has 50 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.


Page last updated 08/02/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top